» Articles » PMID: 34946857

Co-Occurrence of Fragile X Syndrome with a Second Genetic Condition: Three Independent Cases of Double Diagnosis

Abstract

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and autism caused by the instability of a CGG trinucleotide repeat in exon 1 of the gene. The co-occurrence of FXS with other genetic disorders has only been occasionally reported. Here, we describe three independent cases of FXS co-segregation with three different genetic conditions, consisting of Duchenne muscular dystrophy (DMD), --related neurodevelopmental disorder, and 2p25.3 deletion. The co-occurrence of DMD and FXS has been reported only once in a young boy, while in an independent family two affected boys were described, the elder diagnosed with FXS and the younger with DMD. This represents the second case in which both conditions coexist in a 5-year-old boy, inherited from his heterozygous mother. The next double diagnosis had never been reported before: through exome sequencing, a girl with FXS who was of 7 years of age with macrocephaly and severe psychomotor delay was found to carry a variant in the gene. Finally, a maternally inherited 2p25.3 deletion associated with a decreased level of the transcript, only in the patient, was observed in a 33-year-old FXS male with severe seizures compared to his mother and two sex- and age-matched controls. All of these patients represent very rare instances of genetic conditions with clinical features that can be modified by FXS and .

Citing Articles

A Two-Hit Approach Inducing Flurothyl Seizures in Fmr1 Knockout Mice Impacts Anxiety and Repetitive Behaviors.

Blandin K, Narvaiz D, Sullens D, Womble P, Hodges S, Binder M Brain Sci. 2024; 14(9).

PMID: 39335388 PMC: 11429635. DOI: 10.3390/brainsci14090892.


Identification of two novel autism genes, and , in Qatar simplex families through exome sequencing.

Gupta V, Ben-Mahmoud A, Ku B, Velayutham D, Jan Z, Yousef Aden A Front Psychiatry. 2023; 14:1251884.

PMID: 38025430 PMC: 10644705. DOI: 10.3389/fpsyt.2023.1251884.


Phenotypic variability to medication management: an update on fragile X syndrome.

Elhawary N, AlJahdali I, Abumansour I, Azher Z, Falemban A, Madani W Hum Genomics. 2023; 17(1):60.

PMID: 37420260 PMC: 10329374. DOI: 10.1186/s40246-023-00507-2.


Editorial for the Fragile X Syndrome Genetics Special Issue: May 2023.

Godler D, Brown W Genes (Basel). 2023; 14(6).

PMID: 37372328 PMC: 10297929. DOI: 10.3390/genes14061148.

References
1.
Mendell J, Lloyd-Puryear M . Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013; 48(1):21-6. DOI: 10.1002/mus.23810. View

2.
Boland M, Nazor K, Tran H, Szucs A, Lynch C, Paredes R . Molecular analyses of neurogenic defects in a human pluripotent stem cell model of fragile X syndrome. Brain. 2017; 140(3):582-598. PMC: 5837342. DOI: 10.1093/brain/aww357. View

3.
Katayama Y, Tran V, Hoan N, Zhang Z, Goji K, Yagi M . Co-occurrence of mutations in both dystrophin- and androgen-receptor genes is a novel cause of female Duchenne muscular dystrophy. Hum Genet. 2006; 119(5):516-9. DOI: 10.1007/s00439-006-0159-4. View

4.
Loveday C, Tatton-Brown K, Clarke M, Westwood I, Renwick A, Ramsay E . Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth. Hum Mol Genet. 2015; 24(17):4775-9. PMC: 4527483. DOI: 10.1093/hmg/ddv182. View

5.
Hoffman E, Brown Jr R, Kunkel L . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51(6):919-28. DOI: 10.1016/0092-8674(87)90579-4. View